Skip to Main Content

Paper Details

Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
Br J Haematol
1
2024
Author NameAffiliation
Gautam BorthakurThe University of Texas MD Anderson Cancer Center
Farhad RavandiThe University of Texas MD Anderson Cancer Center
Hagop KantarjianThe University of Texas MD Anderson Cancer Center
Guillermo Garcia-ManeroThe University of Texas MD Anderson Cancer Center
  • 1 - 4

Datasets

Release 1.2